What Clopivas-AP 150 Treats: Main Uses and Benefits

Clopivas-AP 150 is a specialized Dual Antiplatelet Therapy (DAPT) used in adults. It provides supportive therapeutic benefits for managing the risk of cardiovascular and cerebrovascular events. The core benefit is long-term secondary prevention—contributing to the reduction of the risk of serious vascular events in high-risk patients.

It is primarily applied in conditions presenting with symptoms related to systemic imbalance, such as the chronic risk of Atherothrombotic Events, including Myocardial Infarction (heart attack), Ischemic Stroke, or Peripheral Arterial Disease (PAD). It is also commonly used as part of the immediate and continuing care for patients diagnosed with Acute Coronary Syndromes (ACS), and for post-procedural maintenance following interventions like stent placement (PCI). The therapy contributes to the ease of overall symptom burden by supporting the management of the risk of recurrent manifestations.

“This supportive therapy is considered relevant for managing the chronic, underlying risk associated with established vascular disease.”

Quick Fact: Therapeutic Focus
Primary Focus	Secondary prevention of atherothrombotic events
Clinical Context	Post-MI, post-stroke, post-stenting, Acute Coronary Syndrome
Patient Benefit	Supports the reduction of the risk of recurrent vascular events

The eligibility for Clopivas-AP 150, a fixed-dose combination of Clopidogrel and Aspirin (ASA), is strictly defined by regulatory authorities based on official prescribing information. The medicine is indicated for use exclusively in adult patients.

---

Populations for Whom Use is Contraindicated

Absolute non-eligibility applies to patients with active pathological bleeding, such as bleeding peptic ulcers or intracranial haemorrhage. The medicine is also contraindicated in patients with severe hepatic impairment or severe renal impairment (creatinine clearance < 30 ml/min). Non-eligibility includes individuals with known hypersensitivity to clopidogrel, aspirin, or other NSAIDs, and those with the syndrome of asthma and nasal polyps.

---

Age and Physiological Status

Use is generally not recommended for children and adolescents under 18 years, as safety and efficacy have not been established in this age group. The medicine is contraindicated during the third trimester of pregnancy and is not recommended for women who are breastfeeding. Use requires caution in populations with mild to moderate organ impairment or a history of conditions predisposing to bleeding.

Interactions with other medicines and products

Official regulatory information describes specific interaction patterns for Clopivas-AP 150 (Clopidogrel and Aspirin FDC) that modify drug exposure or bleeding risk.

Contraindicated and Restricted Combinations

Co-administration with Omeprazole and Esomeprazole is formally contraindicated. This restriction is based on a pharmacokinetic interaction where these medicines significantly inhibit the CYP2C19 enzyme, which is required for clopidogrel activation, thus reducing its active metabolite exposure. The combination is also restricted with other Oral Anticoagulants and in cases of active pathological bleeding (e.g., peptic ulcer) due to severe hemorrhagic risk.

️ Documented Bleeding Risk Interactions

Concomitant use with several drug classes results in a pharmacodynamic interaction that elevates the risk of bleeding:

• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including Ibuprofen and Naproxen.
• Heparin and Thrombolytics.
• Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs).

Exposure and Timing Rules

Other CYP2C19 inhibitors like Fluconazole are officially documented to reduce the active metabolite exposure of clopidogrel. Morphine co-administration is noted to result in reduced and delayed exposure to the active metabolite. For NSAIDs like Ibuprofen, a timing rule exists: administration should occur at least 2 hours after the dose of the Aspirin-containing product. Use with alcohol is generally cautioned against due to the risk of increased gastrointestinal bleeding.

Clopivas-AP 150 is a fixed-dose combination of Clopidogrel and Aspirin that modulates platelet function via two distinct, synergistic pathways.

Clopidogrel is an inactive prodrug that undergoes hepatic bioactivation, primarily by cytochrome P450 enzymes, to form an active thiol metabolite. This active metabolite acts as an irreversible antagonist by selectively binding to the platelet P2Y12 adenosine diphosphate (ADP) receptor. This binding prevents the subsequent ADP-mediated signaling cascade, which includes the activation of the glycoprotein IIb/IIIa (GPIIb/IIIa) receptor complex. The irreversible inhibition lasts for the lifespan of the platelet.

Aspirin acts as an irreversible inhibitor of the platelet cyclooxygenase-1 (COX-1) enzyme. This acetylation prevents COX-1 from catalyzing the conversion of arachidonic acid into Thromboxane A2 ( TxA2), a potent vasoconstrictor and inducer of platelet aggregation. Similar to clopidogrel, this inhibition persists for the life of the platelet.

The combined action of both agents significantly limits the final common pathway of platelet aggregation and subsequent thrombus formation, resulting in system-level physiological modulation characterized by decreased blood viscosity and resistance to blood flow.

How to Use Clopivas-AP 150

The administration of the Clopidogrel and Acetylsalicylic Acid (ASA) fixed-dose combination (FDC) follows standardized protocols, generally for the continuation of therapy after initial treatment.

---

Administration Scope

Instruction	Detail
Route of administration	Oral use, by swallowing the tablet.
Dosing schedule	The standard adult maintenance regimen is one FDC tablet taken once daily (QD), typically containing Clopidogrel 75 mg and Aspirin 75 mg or 100 mg.
Timing in relation to meals	The tablet may be taken with or without food.
Age-group administration rules	The safety and efficacy of the FDC have not been established in children and adolescents under 18 years old, and use is not recommended in this population.
Missed-dose rules	If a dose is missed by less than 12 hours of the regular time, it should be taken immediately, and the next dose resumed at the scheduled time. If the dose is missed by more than 12 hours, the missed dose is skipped, and the regular schedule is continued (do not double the dose).
Special procedural conditions	The standard duration for maintenance may extend for up to 12 months following an acute coronary syndrome event.

---

Instruction Classifications (High-Level)

Classification	Detail
Administration method type	Oral (Solid dosage form)
Frequency pattern	Once daily (QD)
Regulatory basis	Standard pharmaceutical labeling
Use-context constraints	Used only after the initial therapy with the individual components has been established.

Standard administration protocols establish a framework for the long-term use of this dual antiplatelet combination. This structure mandates a single, fixed-strength tablet taken once every 24 hours, defining the quantities of active ingredients and the required frequency for the maintenance phase of therapy. Clinical protocols also set explicit, high-level rules for managing dose timing and provide information on the typical duration of this regimen.

Research Evidence / Overview of Studies for Clopivas-AP 150

Research Evidence for Acute Coronary Syndromes (ACS)

The research examining this dual antiplatelet strategy in conditions such as Acute Coronary Syndromes (ACS) primarily involves large-scale, controlled clinical trials. These studies tracked what happens to groups of adult patients diagnosed with heart attack or unstable angina. The main outcomes research examined included the measured rates of recurrent Myocardial Infarction (MI), Ischemic Stroke, and Cardiovascular Death. A key limitation is that most data used for regulatory review were derived from trials using the separate Clopidogrel and Aspirin tablets, not the fixed-dose combination (FDC).

Evidence Supporting Post-Procedure Maintenance (After Stent Placement)

Numerous large-scale research studies were conducted to evaluate the maintenance phase following a percutaneous coronary intervention (PCI). The research tracked the measured frequency of Stent Thrombosis and the overall rates of Major Adverse Cardiovascular and Cerebrovascular Events (MACCE). Findings were noted to vary across studies that explored differences between therapy durations (for example, comparing 6-month versus 12-month periods). There is limited information specifically comparing the long-term outcomes of the FDC tablet versus the two separate tablets.

Studies for Recent Stroke and Transient Ischemic Attack (TIA)

For patients who have recently experienced a minor ischemic stroke or a TIA, research examined the use of this dual antiplatelet approach as a short-term, intensive strategy, typically starting within 48 hours. The primary outcome tracked was the measured rate of recurrent Ischemic Stroke. Research also documented that the dual therapy was associated with a measured increase in the occurrence of Hemorrhagic Stroke compared to monotherapy groups. Subgroup findings are uncertain for patients with higher stroke severity.

Long-Term Research and Study Follow-up

Research has explored the anti-clotting approach over defined time intervals, but long-term effects are not fully established for all indications. For post-stenting maintenance, observational tracking and comparative trials often extend to several years, with the specific goal of understanding outcomes after the initial maintenance period is complete. Follow-up durations for recent stroke or TIA were primarily limited to the short-term window of up to 90 days.

Evidence in Specific Patient Populations and Research Uncertainty

The major trials involved broad groups of adult patients with established vascular conditions, including older adults. Data for certain groups remain insufficient. Furthermore, data are still emerging regarding the optimal duration of dual antiplatelet therapy for different clinical scenarios, as findings were mixed across some extended-duration studies. Research provides context but does not determine whether an individual will respond similarly.

Key Studies & References

1. Dual Antiplatelet Therapy (DAPT) in Cardiovascular Disease: A Clinical Review

Common questions about Clopivas-AP 150 (FAQ)

Q: What are the most common side effects of Clopivas-AP 150 that people experience?

A: According to official product information, the most commonly reported adverse reactions are those related to bleeding, such as bruising and nosebleeds. Other commonly reported effects may include gastrointestinal symptoms such as diarrhea, abdominal pain, and dyspepsia (indigestion), along with headache and dizziness.

Q: Are there any common over-the-counter pain relievers that should be avoided while on Clopivas-AP 150?

A: Official regulatory warnings advise that Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen and naproxen, are generally not recommended. Using them at the same time as this medicine increases the risk of bleeding.

Q: Is it normal to have increased bruising when taking Clopivas-AP 150?

A: Bruising (contusion) is officially listed as a common side effect. Because this medicine works by affecting the ability of platelets to clot, some increased bruising is recognized as a common effect of taking this type of medication.

Q: Does Clopivas-AP 150 interact with alcohol consumption?

A: Official information includes a caution regarding alcohol use. Alcohol consumption is generally advised against because it can increase the risk of gastrointestinal bleeding, which is a known side effect of the aspirin component of the tablet.

Q: Is Clopivas-AP 150 a blood thinner, and how does it compare to other common ones?

A: Clopivas-AP 150 is classified as a Dual Antiplatelet Agent, not a traditional 'blood thinner' (anticoagulant). It works by stopping blood platelets from sticking together to form a clot. This is a different anti-clotting mechanism than that of many anticoagulant agents.

Q: How quickly does Clopivas-AP 150 start working to prevent clots?

A: When the components are given as an initial loading dose, the antiplatelet effect of clopidogrel is typically observed within two hours. The fixed-dose combination is primarily intended for maintenance therapy following initial treatment.

Q: What happens if I stop taking Clopivas-AP 150 suddenly?

A: Regulatory warnings state that stopping this antiplatelet therapy may significantly increase the risk of a serious cardiovascular event, such as a heart attack or a stroke. Discontinuing this medicine should only be done under the guidance of a healthcare professional.

Q: Is Clopivas-AP 150 safe for people with kidney problems?

A: Official labeling states that the medicine is contraindicated (not allowed) in patients with severe renal impairment (a high degree of kidney failure). Official guidance notes that experience with the medicine is limited in patients with mild to moderate kidney impairment.

Q: What are the long-term effects of taking Clopivas-AP 150?

A: The long-term effects of therapy are primarily related to the continued risk of bleeding over time. Serious bleeding events, particularly in the gastrointestinal tract or brain, are a principal long-term risk noted in safety profiles.

Q: Does Clopivas-AP 150 cause stomach upset or digestive issues?

A: Yes, gastrointestinal (digestive) issues are very common adverse reactions. This includes abdominal pain, diarrhea, and dyspepsia (stomach upset or indigestion), according to official reports.

Q: Is dizziness a common side effect of Clopivas-AP 150?

A: Yes, dizziness is officially listed as a common adverse reaction in the regulatory safety profile of the medicine.

Q: Can Clopivas-AP 150 affect my liver function?

A: Official product information notes that the medicine is not recommended for people with severe hepatic (liver) impairment. Severe hepatic failure has been reported very rarely.

Q: Does Clopivas-AP 150 have any known drug-food interactions besides alcohol?

A: Regulatory pharmacokinetics data indicates that the tablet may be taken with or without food. Official prescribing information does not list general dietary restrictions, aside from the caution related to alcohol.

Q: Why is the dosage '150' and what does that number represent?

A: The number '150' in the name refers to the total combined weight of the two active ingredients in the tablet. This is usually composed of 75 mg of clopidogrel and 75 mg of aspirin.

Q: Are there any dietary restrictions necessary while on Clopivas-AP 150?

A: Official prescribing information does not list any specific dietary restrictions. The tablet is approved to be taken with or without food.

Q: Is Clopivas-AP 150 similar to other common heart medications like statins?

A: Clopivas-AP 150 is fundamentally different from statins. It is an antiplatelet agent used to prevent blood clots. Statins are a different class of medicine primarily used to lower cholesterol levels.

Q: Does Clopivas-AP 150 prevent all types of blood clots?

A: The medicine is an antiplatelet agent that primarily works to prevent the formation of arterial blood clots (thrombi). It is specifically indicated for cardiovascular conditions and does not necessarily prevent all types of clots in all parts of the circulatory system.

Q: Can Clopivas-AP 150 be crushed or split, or must it be swallowed whole?

A: Official guidance recommends that the film-coated tablet be swallowed whole with water. It is not generally recommended to modify the tablet.

Q: What should I do if I have accidental cuts or minor bleeding while taking Clopivas-AP 150?

A: Because the medicine prolongs bleeding time, it is normal for cuts and minor injuries to take longer to stop bleeding. Any unusual or prolonged bleeding that is concerning should be addressed by seeking professional advice.

Q: Is Clopivas-AP 150 safe for elderly patients?

A: Official information states that the medicine is indicated for use in adults, including older adults, and was studied in this population. Caution is generally noted for older adults due to the increased risk of bleeding observed in this population.

Q: What is the difference between Clopivas-AP 150 and lower-dose versions?

A: The difference between strengths is the amount of the active ingredients, clopidogrel and aspirin, in each tablet. The appropriate dose is determined by a healthcare provider based on the patient's specific clinical needs.

Q: Is nosebleeds a common side effect of Clopivas-AP 150?

A: Yes, nosebleeds (epistaxis) are officially listed as a common adverse reaction in the regulatory safety profile of the medicine.

Q: What is the maximum recommended duration for taking Clopivas-AP 150?

A: The recommended duration of therapy is not a single maximum number, but is specific to the condition being treated. Clinical trial data often show maintenance therapy lasting up to 12 months following an acute coronary syndrome event, but the exact duration is condition-specific.

Q: Does Clopivas-AP 150 affect the ability to drive or operate machinery?

A: Official regulatory information specifies that this medicine has no or negligible influence on the ability of a person to drive or use machinery.

Q: Are there any documented cases of Clopivas-AP 150 resistance?

A: Official labels note that clopidogrel may be less effective in certain individuals who are poor metabolizers of the CYP2C19 enzyme. This difference in metabolism may result in a diminished antiplatelet response.

Q: Is it possible to develop an allergy to Clopivas-AP 150?

A: Yes, it is possible. Official prescribing information states that the medicine is contraindicated in individuals with known hypersensitivity (an allergy) to clopidogrel, aspirin, or other related anti-inflammatory drugs.

Storage Conditions

Clopivas-AP 150 must be stored according to official regulatory labeling to maintain the stability of its active components, Clopidogrel and Aspirin. The medicine must be kept at a temperature not exceeding 30°C (86°F), consistent with Controlled Room Temperature standards.

It is mandatory to keep the tablets in the original container/blister pack to ensure protection from light and moisture. Excessive heat and damp environments, such as a bathroom or a car on a hot day, must be avoided as they can cause degradation.

Disposal and Safety

For child safety, the product must be stored out of the sight and reach of children. Unused or expired tablets should not be disposed of in household trash or poured into a drain/wastewater.

Regulatory instructions require that any unused medicine be disposed of in accordance with local requirements for pharmaceutical waste, such as authorized medicine take-back programs.